Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fox Corp Class A (FOXA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Fox Corp Class ATrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Fox Corp Class A vs Regeneron Pharmaceuticals Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $25.05B), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.3× Fox Corp Class A's market cap, and Fox Corp Class A pays the higher dividend (0.91%). Which is the better fit depends on your goals.

FOXAREGN
Market Cap
$25.05B$83.19B
Sector
MediaHealth
52-Week High
$76.11$812.27
52-Week Low
$48.79$545.94
Enterprise Value
$28.41B$77.90B
Dividend Yield
0.91%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fox Corp Class A

FOXA trades at $64.03, up 3.63% on strong Q4 2026 earnings beats driven by World Cup advertising and Tubi streaming growth. The stock shows bullish technical momentum with a consensus price target of $65.33, supported by a 50% buy rating from analysts. Revenue grew to $16.30B in 2025, with net income margin expanding to 13.88%, though 2026 projections indicate moderation.

Outlook remains positive with digital ad momentum and strategic initiatives, but risks include sports cost pressures and cyclical advertising dependence. The current valuation at a P/E of 16.52 appears reasonable relative to earnings growth, offering potential upside if execution continues.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fox Corp Class A

Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.

Read more on FOXA

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN